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Abstract
Background: After two studies reporting response rates higher than 70% in HER2-positive metastatic
breast cancer with weekly trastuzumab and vinorelbine, we planned a phase 2 study to test activity of the
same combination, with trastuzumab given every 3 weeks.
Methods: Patients with HER2-positive metastatic breast cancer (3+ at immunohistochemistry or positive
at fluorescence in situ hybridization), PS ≤2, normal left-ventricular ejection fraction (LVEF) and no more
than one chemotherapy line for metastatic disease were eligible. Vinorelbine (30 mg/m2) was given on days
1&8 every 21 and trastuzumab (8 mg/kg day 1, then 6 mg/kg) every 21 days). A single-stage phase 2 design,
with p0 = 0.45, p1 = 0.65, type I and II error = 0.10, was applied; 22 objective responses were required in
39 patients.
Results: From Nov 2002 to May 2005, 50 patients were enrolled, with a median age of 54 years (range
31–81). Among 40 patients eligible for response assessment, there were 7 complete and 13 partial
responses (overall response rate 50%; 95% exact CI 33.8–66.2); 11 patients had disease stabilization, lasting
more than 6 months in 10 cases. Response rate did not vary according to patients and tumor
characteristics, type and amount of previous chemotherapy. Within the whole series, median progression-
free survival was 9.6 months (95% CI 7.3–12.3), median overall survival 22.7 months (95% CI 19.5-NA).
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Fifteen patients (30%) developed brain metastases at a median time of 12 months (range 1–25). There was
one toxic death due to renal failure in a patient receiving concomitant pamidronate. Twenty-three patients
(46%) had grade 3–4 neutropenia, 2 (4%) grade 3 anemia, 4 (8%) febrile neutropenia. Two patients stopped
treatment because of grade 2 decline of LVEF and one patient because of grade 2 liver toxicity concomitant
with a grade 1 decline of LVEF. One patient stopped trastuzumab after 50 cycles because of grade 1 decline
of LVEF.
Conclusion: Although lower than in initial studies, activity of 3-weekly trastuzumab plus vinorelbine fell
within the range of results reported with weekly schedules. Toxicity was prevalently manageable. This
combination is safe and active for metastatic breast cancer patients who received adjuvant taxanes with
anthracyclines.
Background
Metastatic breast cancer is an incurable disease, frequently
treated with chemotherapy, particularly when hormonal
treatment has failed or is not indicated because of lack of
estrogen receptor expression in the tumor.
One of the major advances for the treatment of metastatic
breast cancer has been the introduction of trastuzumab, a
monoclonal antibody directed against the HER2 extracel-
lular domain. Tumors with HER2 overexpression or
amplification account for 25–30% of breast cancer and
are a particular subgroup with different prognosis, natural
history and drug sensitivity [1,2]. The combination of
trastuzumab with chemotherapy has been shown to be
effective in the treatment of metastatic breast cancer
patients in a pivotal study, where the monoclonal anti-
body was combined with either adriamycin/cyclophos-
phamide or paclitaxel [3]; significant advantages were
reported for all the efficacy end-points, including quality
of life that has been reported more recently [4].
Following this report, many studies have been conducted
combining trastuzumab with other chemotherapeutic
agents frequently used in breast cancer treatment. Preclin-
ical studies have demonstrated that synergistic effects can
be obtained with the combination of trastuzumab with
vinorelbine or taxanes [5,6].
When we planned the present study, there were reports on
two phase 2 studies of the combination of trastuzumab
and vinorelbine [7,8]. Both studies employed the weekly
schedule of trastuzumab and produced exciting results
with very high response rates even in patients receiving it
as second-line treatment.
Based on such data, we planned a single-centre phase 2
study to test activity and tolerability of the same combina-
tion of trastuzumab and vinorelbine, with trastuzumab
given 3-weekly, as first- or second-line treatment of meta-
static breast cancer patients overexpressing HER2. The 3-
weekly schedule of trastuzumab had been shown to have
similar pharmacokinetic profile and activity to weekly
schedule in a previous phase two study [9] but could be
more convenient for patients, and potentially less costly.
Methods
Eligibility criteria
Patients were eligible if they had histologically proven,
metastatic breast cancer and overexpression of HER2
defined as score 3+ by immunohistochemistry (IHC) or as
gene amplification by fluorescence in-situ hybridization
(FISH). They could have received no more than one chem-
otherapy line for metastatic disease (also neo-adjuvant
and/or adjuvant chemotherapy were allowed). Other eli-
gibility criteria included: performance status ≤2 according
to the Eastern Cooperative Oncology group (ECOG) scale,
adequate bone marrow (absolute neutrophil count
≥1500/mm3, platelets ≥100000/mm3 and hemoglobin ≥8
g/dl), renal (serum creatinine ≤1.5 × upper normal limit)
and hepatic (SGOT and SGPT ≤2.5 × upper normal limit
and bilirubin ≤1.5 × upper normal limit, unless due to
liver metastases) function. Patients were excluded if they
had left ventricular ejection fraction (LVEF) <50% as
determined by echocardiography, symptomatic brain
metastases, a positive history of other types of cancer
(except for radically resected carcinoma-in-situ of the cer-
vix or non-melanoma skin cancer), or previous treatment
with trastuzumab or vinorelbine. Patients with no target
lesions were eligible for toxicity, but not for activity assess-
ment. The study was approved by the Institutional Ethical
Committee and all patients provided written informed
consent before starting study procedures.
Treatment plan, dose modifications and delay
For the first cycle, patients received trastuzumab on day 1
at loading dose of 8 mg/kg in a 90-minute infusion and
vinorelbine on days 2 and 8 at 30 mg/m2. For the subse-
quent every 3 week cycles, trastuzumab was given at dose
of 6 mg/kg on day 1 and vinorelbine was given on days 1
and 8. Trastuzumab was administered as a 90-minute
infusion prior to vinorelbine for all cycles following the
initial dose. Vinorelbine was administered for a maxi-
mum of 9 cycles, while trastuzumab was continued until
disease progression or unacceptable toxicity.
Dose adjustments were planned only for vinorelbine and
were dependent on the type and grade of toxicity
observed: vinorelbine dose was reduced by 20% for neu-
trophil count between 1000 and 1499/mm3 or platelet
count between 75000 and 99000/mm3. In case of neu-BMC Cancer 2007, 7:50 http://www.biomedcentral.com/1471-2407/7/50
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trophil count <1000/mm3  or platelets <75000/mm3,
vinorelbine was delayed for one week (day 1) or omitted
(day 8). Patients with treatment-related grade ≥2 non-
hematologic toxicity (except LVEF alterations) did not
receive vinorelbine and trastuzumab therapy until the tox-
icity resolved to grade 1 or lower. If toxicity failed to
resolve after a 2-week treatment delay, patients were taken
off protocol.
In case of reduction of LVEF ≤44%, treatment with trastu-
zumab was stopped and LVEF measurements were
repeated after 3 weeks; if LVEF was confirmed ≤44% or
<50% with a decrease ≥10 points as compared to baseline,
trastuzumab treatment was definitively stopped. If LVEF
was ≥50% or >44% with a decrease <10 points as com-
pared to baseline, trastuzumab was resumed with an
intensive cardiac surveillance.
Hematologic support with G-CSF and recombinant
human erythropoietin was used according to standard
guidelines.
Pre-treatment procedures
Pre-treatment staging was performed within one month
before starting therapy and included a complete history
and physical examination, complete blood cell counts
and serum chemistries, ECG, LVEF evaluated by echocar-
diography with biplane method according to Simpson's
rule, chest X-ray, complete abdominal ultrasound, bone
scan. Other exams were performed if clinically indicated.
To define dominant metastatic site, visceral sites (lung,
liver, brain, pleura) prevailed over all other sites, and
bone prevailed over soft tissues (breast, nodes, skin).
The HER2 status was assessed on primary breast tumor
after resection or on core biopsy, by immunohistochemis-
try (IHC) and/or fluorescence in situ hybridization (FISH)
on formalin-fixed paraffin-embedded tissue according to
the guidelines reported in 2000 by Ellis et al [10]. The
level of staining of non-neoplastic epithelium present on
the same slide was taken into consideration.
IHC was performed using DAKO HercepTest approved in
1998 by the Food and Drug Administration. Scores of 2+
and 3+ were considered positive (overexpression). HER-2/
neu gene amplification by FISH was performed for all
cases of 2+ score. FISH analysis was performed using the
Vysis PathVysion HER2 probe kit according to manufac-
turer's instructions. Two pathologists evaluated FISH and
IHC analyses independently.
Evaluation of response and toxicity
Response assessment was planned after the completion of
the 3rd and 6th cycles of chemotherapy, repeating the stag-
ing procedures. Response was evaluated according to
RECIST (Response Evaluation Criteria in Solid Tumor)
guidelines [11]. Tumor lesions were categorized as meas-
urable if they could be accurately measured in at least one
dimension as ≥20 mm with conventional techniques or as
≥10 mm with spiral CT. All other tumor lesions, including
small lesions and truly non-measurable lesions, were cat-
egorized as non-target lesions.
Physical examination and vital signs were recorded before
each cycle of chemotherapy. Complete blood cell count
was measured before every cycle and weekly, biochemistry
and urine analysis before day 1 of each cycle. Cardiac
assessment was performed by clinical evaluation, electro-
cardiography and echocardiography with LVEF measure-
ments every 3 cycles or when clinically indicated. Toxicity
was graded according to National Cancer Institute Com-
mon Toxicity Criteria (NCI CTC), version 2.0.
Study design and sample size
A single-stage, phase 2 study design was applied. The pri-
mary end-point was response rate. With minimum accept-
able proportion of response (P0) of 0.45, desired
proportion of response (P1) of 0.65, α error 0.10, β error
0.10, 39 patients assessable for response were needed. For
defining the study as positive, at least 22 objective
responses should be recorded. Exact 95% confidence
interval (CI) were calculated. Secondary end-points were
toxicity, progression-free survival, defined as the time
from the date of enrolment and the date of the first pro-
gression, and overall survival, defined as the time between
the date of study enrolment and the date of death. Pro-
gression-free and overall survival were estimated using the
Kaplan-Meier method [12].
Results
Patients characteristics
From November 4th, 2002 to May 11th, 2005, 50 patients
entered the study, of whom 40 were eligible for response
assessment. Main baseline characteristics of the patients
are reported in Table 1. Median age was 54 years (range
31–81); one-fifth of patients were older than 65. ECOG
performance status was 0 in 41 patients, 1 in 7 patients
and 2 in 2 patients. Nine patients, who were ineligible for
other standard treatments because of advanced age or
concomitant cardiologic disease, were chemo-naive;
among the remaining 41 patients, 37 had received previ-
ous anthracyclines and 13 had received taxanes. Overall,
considering neoadjuvant, adjuvant and metastatic set-
tings, 26 patients had received one prior course of chem-
otherapy and 15 had received two courses. No patient had
received prior trastuzumab or vinorelbine. More than half
of the patients had metastatic disease to a single organ.
The predominant metastatic sites were visceral, and 8
patients had bone metastases combined with visceral
sites.
Compliance and toxicity
A total number of 315 cycles of chemotherapy (median
number of 9 cycles per patient, range 1 to 9) and of 487
administrations of trastuzumab (median number of 9
administrations per patient, range 1–50) were given to theBMC Cancer 2007, 7:50 http://www.biomedcentral.com/1471-2407/7/50
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50 patients. Reasons for treatment discontinuation were
one toxic death, one early death due to progression of dis-
ease, 8 non fatal toxicity, 10 progression of disease and
one patient refusal. G-CSF support was required in 72
cycles of chemotherapy (22.6%). The planned dose inten-
sity of vinorelbine was 20 mg/m2/wk and the median
dose actually delivered was 15.7 mg/m2/wk; therefore the
relative dose intensity was 0.79. The planned dose inten-
sity of trastuzumab was 2 mg/kg/wk and the median dose
actually delivered was 1.84 mg/kg/wk with a relative dose
intensity of 0.9.
Hematological and non-hematological toxicities are
reported in table 2.
Grade 3–4 neutropenia occurred in almost the half of
patients (46%) and 4 patients developed febrile neutrope-
nia. Grade 4 anemia and thrombocytopenia were never
observed.
The most common non-hematological toxicities were
fatigue, constipation and abdominal pain. A toxic death
was observed after the first cycle of chemotherapy, due to
acute renal failure in a patient with bone metastases who
was concomitantly treated with pamidronate. One patient
without liver metastases developed grade 3 liver toxicity
after the fifth cycle of chemotherapy due to a re-exacerba-
tion of HCV-related hepatitis.
Patients were strictly monitored with frequent evaluation
of LVEF and a treatment related cardiac event was recog-
nized in four patients. During the period of combined
treatment there were three cases of LVEF decline. The first
patient presented with tachycardia and an echocardio-
gram showed a reduction of resting LVEF >20% from
baseline value (grade 2 according to NCI-CTC) after the
third cycle; she had hypertension and retro-sternal goitre
with hyperthyroidism as comorbidity and had received
adjuvant epirubicin (total dose 480 mg/m2); the LVEF
reduction was persistent for at least 9 months after treat-
ment. The second event was an asymptomatic grade 2
decline of LVEF after the third cycle, that was persistent
three weeks after interruption of treatment; this patient,
who had been treated with adjuvant epirubicin for a total
dose of 400 mg/m2, developed brain metastases and died
four months later. The third cardiac event was a grade 1
asymptomatic decline of LVEF after three cycles, in a
patient who had not received previous anthracyclines; this
patient was taken off from the study because of concomi-
tant grade 2 liver toxicity. One more event of grade 1 LVEF
decline was reported in a patient after 50 overall cycles of
trastuzumab, with LVEF declining from 80%, at baseline,
to 66%.
Activity
Among 40 eligible patients, a complete response was
observed in 7 (17.5%) and a partial response in 13
(32.5%) cases, for an overall response rate of 50% (95%
exact CI 33.8–66.2). Median duration of response among
patients treated as first-line was 12 months (range 5–27).
Disease stabilization was obtained in 11 patients, lasting
more than 6 months in 10 of them (range 3–13).
Ten patients were not eligible for response assessment
because of the absence of target lesions; according to the
outcome of non-target lesions, 4 complete responses (last-
ing 7, 12, 12 and 43 months), 2 non response/non pro-
gression (lasting 8 and 12 months) and 3 progressions
were reported, while one patient was not reassessed
because of unacceptable toxicity (febrile neutropenia and
abdominal pain) before the third cycle administration.
Interestingly, one patient who achieved a complete
Table 1: Baseline characteristics of patients (N = 50)
Variable
Age, n (%)
<65 40 (80)
65 or more 10 (20)
Histotype, n (%)
Ductal 41 (82)
Lobular 6 (12)
Other 3 (6)
ER status, n (%)
Negative 19 (38)
Positive 30 (60)
Unknown 1 (2)
Performance status, n (%)
04 1 ( 8 2 )
17 ( 1 4 )
22 ( 4 )
HER2 status, n (%)
Score 3+ by IHC 47 (94)
Score 2+ and positive by FISH 3 (6)
Time from breast cancer diagnosis, n (%)
<2 years 19 (38)
2 years or more 31 (62)
Previous chemotherapy, n (%)
No 9 (18)
Yes 41 (82)
By type of drugs
CMF 4 (8)
with anthracycline 24 (48)
with anthracycline and taxane 13 (26)
By number of lines of chemotherapy
one line 26 (52)
two lines 15 (30)
Extension of disease, n (%)
By number of involved organs
12 7 ( 5 4 )
21 6 ( 3 2 )
37 ( 1 4 )
By dominant metastatic site
soft tissues 13 (26)
viscera 37 (74)
Eligible for response assessment, n (%)
No 10 (20)
Yes 40 (80)
IHC: immunohistochemistry, FISH: fluorescence in situ hybridizationBMC Cancer 2007, 7:50 http://www.biomedcentral.com/1471-2407/7/50
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response continued trastuzumab until 50 administra-
tions; treatment was then interrupted due to an asympto-
matic reduction of LVEF from 80% to 66%.
In table 3, the rate of responding patients in the whole
series is scattered by main baseline characteristics of
patients, tumor and pretreatment that could potentially
affect the chance of response. Confidence intervals sug-
gests that none of the considered variables significantly
affected the chance of response. However, with limita-
tions due to the small sample size, it appears that elderly
patients, those with a poorer performance status and
those with a longer time from breast cancer onset had
lower response rates.
Brain was the first site of progression in 9 cases, but, over-
all 15 patients (30%) developed brain metastases, at times
ranging from 1 to 25 months (median 12 months).
Up to July 1st 2006, 40 patients had suffered progression
of disease and 24 patients had died. Median progression-
free survival was 9.6 months (95% CI: 7.3–12.3). Median
overall survival was 22.7 months (95% CI: 19.5-NA). Kap-
lan-Meier's estimated curves of progression-free and over-
all survival are reported in Figures 1 and 2.
Discussion
In the present study we tested the combination of trastu-
zumab plus vinorelbine in the treatment of HER-2 posi-
tive metastatic breast cancer. The response rate we found
was lower than in the initial phase 2 studies of this com-
bination [7,8] but nevertheless compatible with a positive
interpretation, given that in the near future the proportion
of metastatic breast cancer patients who are eligible for a
treatment with trastuzumab, but have already received
taxanes as adjuvant, will increase.
Chan recently reviewed literature available on the combi-
nation of trastuzumab with vinorelbine [13]. She found
eleven trials of the weekly schedule, but the present one
(reported in a preliminary form to the National Italian
Congress in 2004) was the only one testing a 3-weekly
schedule of trastuzumab. Among the eleven studies of the
weekly schedule, response rate ranged from 44% to 86%;
complete response rate ranged from 3% to 15%; grade 3–
4 neutropenia was reported in 23% to 84% of patients;
febrile neutropenia in less than 5% of patients. Our results
compare well with such data; the overall response rate
falls within the range of previously reported studies,
although at the lower end of the values; the complete
response rate is higher than previous data; neutropenia
incidence is in the midrange of previous results; febrile
neutropenia has been more frequent in our study.
While the administration of vinorelbine on days 1 and 8
every 3 weeks is a commonly used scheme, the use of tras-
tuzumab every 3 weeks is innovative in combination with
vinorelbine. Only one publication has recently focused on
a similar schedule; Bartsch et al [14] reported a chart
review showing that out of 17 patients, treated with oral
vinorelbine on days 1 and 8 combined with 3-weekly tras-
tuzumab, 9 had an objective response that was complete
in 4 cases (23.5%). However, the retrospective nature and
the small number of patients require caution in the inter-
pretation of these data. The schedule that we tested differs
from previous studies in several aspects. Two studies have
been reported addressing pharmacokinetics (PK), safety
and activity of the 3-weekly trastuzumab that we used. In
the first one [9], trastuzumab was combined with paclit-
axel in 36 patients; PK data showed that plasma levels for
the drug were sufficiently high at the end of cycle 1 and
suggested that half-life of trastuzumab combined with
paclitaxel might be 18 to 27 days, encouraging the use of
the 3-weekly schedule; one-third of patients had a >15%
decline of LVEF, but only one developed symptomatic
heart failure. The second paper [15] reported data on tras-
tuzumab given as single agent. In this study, with 105
patients, there was no significant change of LVEF, and PK
data confirmed that that the 3-weekly schedule produced
an exposure to the drug similar to the weekly one.
Table 2: Worst per-patient toxicity within the period of 
combined treatment (N = 50)
Type of toxicity Patients (%)
1234 5
Allergy 2 (4) 2 (4) 2 (4) - -
Anemia 18 (36) 11 (22) 2 (4) - -
Leukopenia - 11 (22) 7 (14) 1 (2) -
Neutropenia - 5 (10) 13 (26) 10 (20) -
Febrile neutropenia - - 4 (8) - -
Platelets 1 (2) 2 (4) - -
Cardiac (LVEF decline) 1 (2) 2 (4) - - -
Renal 1 (2) 1 (2) - - 1 (2)
Fatigue 12 (22) 4 (8) - - -
Fever 2 (4) 1 (2) - - -
H a i r  l o s s 1  ( 2 ) --- -
Skin 3 (6) 4 (8) - - -
A n o r e x i a 2  ( 4 ) --- -
Constipation 12 (24) 3 (6) - - -
D i a r r h o e a 3  ( 6 ) --- -
Nausea 5 (10) 2 (4) - - -
Stomatitis 3 (6) - - - -
Vomiting 4 (8) - - - -
Liver 1 (2) 1 (2) 1 (2) - -
Sensorial neuropathy 4 (8) - - - -
Abdominal pain 13 (26) 1 (2) 1 (2)
R B C  t r a n s f u s i o n - -1  ( 2 )- -
RBC = red blood cellBMC Cancer 2007, 7:50 http://www.biomedcentral.com/1471-2407/7/50
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Several retrospective reports in the last years suggested an
increased prevalence of brain metastases in patients
receiving trastuzumab-based therapy for HER2-overex-
pressing metastatic breast cancer [16-19]. The true inci-
dence of brain metastases in breast cancer is not precisely
known, but it's estimated close to 10–15% of patients
even if autopsy series reported rates ranging from 18% to
30% [19]. In our study, the rate of patients who developed
brain metastases was quite high (30%). Our interpreta-
tion is that this only represents an apparent increase of
incidence, probably due to the durable effect of trastuzu-
mab on the other metastatic sites; similar data, indeed,
have been also reported with the introduction of other
highly effective chemotherapies, like platinum-based for
ovarian cancer [20] and taxane-based for breast cancer
[21].
Following the pivotal trial of Slamon et al. [3] and several
other reports, including one recent by Marty et al. testing
the combination of trastuzumab with docetaxel [22], tras-
tuzumab is actually indicated for clinical practice in com-
bination with taxanes. However, such combinations
would not be reasonable for the patients who have
already received taxanes as adjuvant treatment, a group
whose number is going to increase. It must also be consid-
ered that the use of trastuzumab as adjuvant treatment,
prompted by excellent results of the first trials [23,24],
will probably reduce the need of treating metastatic breast
cancer patients with trastuzumab, and other molecules,
like lapatinib [25] or others at a less advanced stage of
development, will be tested. In the meantime, we believe
that the combination of trastuzumab and vinorelbine can
be a rationale and safe approach for the treatment of HER-
Table 3: Rate of responding patients according to baseline characteristics
Variable no. of patients response rate
at risk responding (95% exact CI)
Age
<65 40 21 52.5 (36.1–68.5)
65 or more 10 3 30.0 (6.7–65.2)
Histotype
Ductal 41 20 48.8 (32.9–64.9)
Lobular or other 9 4 44.4 (13.7–78.8)
ER status
Negative 19 9 47.4 (24.5–71.1)
Positive 30 14 46.7 (28.3–65.7)
Performance status
0 41 22 53.7 (37.4–69.3)
1 or 2 9 2 22.2 (2.8–60.0)
Time from breast cancer diagnosis
<2 years 19 12 63.2 (38.4–83.7)
2 years or more 31 12 38.7 (21.8–57.8)
Previous chemotherapy
No 9 4 44.4 (13.7–78.8)
Yes 41 20 48.8 (32.9–64.9)
By type of drugs
CMF 4 2 50.0 (6.8–93.2)
with anthracycline 24 13 54.2 (32.8–74.5)
with anthracycline and taxane 13 5 38.5 (13.9–68.4)
By number of lines of chemotherapy
one line 26 13 50.0 (29.9–70.1)
two lines 15 7 46.7 (21.3–73.4)
Extension of disease
By number of involved organs
1 27 13 48.1 (28.7–68.0)
2 16 7 43.7 (19.7–70.1)
3 7 4 57.1 (18.4–90.1)
By dominant metastatic site
soft tissues 13 7 53.8 (25.1–80.8)
viscera 37 17 45.9 (29.5–63.1)BMC Cancer 2007, 7:50 http://www.biomedcentral.com/1471-2407/7/50
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2 positive metastatic breast cancer patients who have not
received trastuzumab in the adjuvant setting. Further
improvement of the activity of this combination could
derive by the addition of a third drug, like carboplatin that
could be synergistic with trastuzumab [26]; a phase 2 trial
of this 3-drug combination is currently ongoing in our
institution.
Conclusion
The combination of trastuzumab and vinorelbine is an
active and rationale approach in metastatic breast cancer
with a manageable toxicity profile, and can be considered
for patients with HER2-positive breast cancer who have
already received anthracyclines and taxanes.
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Kaplan-Meier estimated overall survival curve (solid line) with 95% confidence limits (dotted lines) Figure 2
Kaplan-Meier estimated overall survival curve (solid line) with 95% confidence limits (dotted lines).
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